Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases.
Laakmann E, Witzel I, Neunhöffer T, Weide R, Schmidt M, Park-Simon TW, Möbus V, Mundhenke C, Polasik A, Lübbe K, Hesse T, Riecke K, Thill M, Fasching PA, Denkert C, Fehm T, Nekljudova V, Rey J, Loibl S, Müller V. Laakmann E, et al. Among authors: fasching pa. Cancers (Basel). 2020 Sep 28;12(10):2787. doi: 10.3390/cancers12102787. Cancers (Basel). 2020. PMID: 32998430 Free PMC article.
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials.
von Minckwitz G, Untch M, Nüesch E, Loibl S, Kaufmann M, Kümmel S, Fasching PA, Eiermann W, Blohmer JU, Costa SD, Mehta K, Hilfrich J, Jackisch C, Gerber B, du Bois A, Huober J, Hanusch C, Konecny G, Fett W, Stickeler E, Harbeck N, Müller V, Jüni P. von Minckwitz G, et al. Among authors: fasching pa. Breast Cancer Res Treat. 2011 Jan;125(1):145-56. doi: 10.1007/s10549-010-1228-x. Epub 2010 Nov 3. Breast Cancer Res Treat. 2011. PMID: 21042932 Free article.
Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Zeitz J, Pantel K, Fehm T; DETECT study group. Müller V, et al. Among authors: fasching pa. Breast Cancer Res. 2011 Jul 11;13(4):R71. doi: 10.1186/bcr2916. Breast Cancer Res. 2011. PMID: 21745383 Free PMC article.
Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy.
Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching PA, Barinoff J, Holms F, Thomssen C, Zahm DM, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G. Guo X, et al. Among authors: fasching pa. Breast Care (Basel). 2011;6(4):279-283. doi: 10.1159/000330946. Epub 2011 Aug 19. Breast Care (Basel). 2011. PMID: 22164126 Free PMC article.
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer JU, Huober J, Hauschild M, Fehm T, Müller BM, Denkert C, Loibl S, Nekljudova V, Untch M; German Breast Group; Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups. von Minckwitz G, et al. Among authors: fasching pa. N Engl J Med. 2012 Jan 26;366(4):299-309. doi: 10.1056/NEJMoa1111065. N Engl J Med. 2012. PMID: 22276820 Free article. Clinical Trial.
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich J, Huober J, Jackisch C, Kaufmann M, Konecny GE, Denkert C, Nekljudova V, Mehta K, Loibl S. von Minckwitz G, et al. Among authors: fasching pa. J Clin Oncol. 2012 May 20;30(15):1796-804. doi: 10.1200/JCO.2011.38.8595. Epub 2012 Apr 16. J Clin Oncol. 2012. PMID: 22508812
The role of genetic breast cancer susceptibility variants as prognostic factors.
Fasching PA, Pharoah PD, Cox A, Nevanlinna H, Bojesen SE, Karn T, Broeks A, van Leeuwen FE, van't Veer LJ, Udo R, Dunning AM, Greco D, Aittomäki K, Blomqvist C, Shah M, Nordestgaard BG, Flyger H, Hopper JL, Southey MC, Apicella C, Garcia-Closas M, Sherman M, Lissowska J, Seynaeve C, Huijts PE, Tollenaar RA, Ziogas A, Ekici AB, Rauh C, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Andrulis IL, Ozcelik H, Mulligan AM, Glendon G, Hall P, Czene K, Liu J, Chang-Claude J, Wang-Gohrke S, Eilber U, Nickels S, Dörk T, Schiekel M, Bremer M, Park-Simon TW, Giles GG, Severi G, Baglietto L, Hooning MJ, Martens JW, Jager A, Kriege M, Lindblom A, Margolin S, Couch FJ, Stevens KN, Olson JE, Kosel M, Cross SS, Balasubramanian SP, Reed MW, Miron A, John EM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Chenevix-Trench G; kConFab Investigators; Lambrechts D, Dieudonne AS, Hatse S, van Limbergen E, Benitez J, Milne RL, Zamora MP, Pérez JI, Bonanni B, Peissel B, Loris B, Peterlongo P, Rajaraman P, Schonfeld SJ, Anton-Culver H, Devilee P, Beckmann MW, Slamon DJ, Phillips KA, Figueroa JD, Humphreys MK, Easton DF, Schmidt MK. Fasching PA, et al. Hum Mol Genet. 2012 Sep 1;21(17):3926-39. doi: 10.1093/hmg/dds159. Epub 2012 Apr 24. Hum Mol Genet. 2012. PMID: 22532573 Free PMC article.
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N. Schuler M, et al. Among authors: fasching pa. Breast Cancer Res Treat. 2012 Aug;134(3):1149-59. doi: 10.1007/s10549-012-2126-1. Epub 2012 Jul 5. Breast Cancer Res Treat. 2012. PMID: 22763464 Free PMC article. Clinical Trial.
Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study.
Müller V, Riethdorf S, Rack B, Janni W, Fasching PA, Solomayer E, Aktas B, Kasimir-Bauer S, Pantel K, Fehm T; DETECT study group. Müller V, et al. Among authors: fasching pa. Breast Cancer Res. 2012 Aug 15;14(4):R118. doi: 10.1186/bcr3243. Breast Cancer Res. 2012. PMID: 22894854 Free PMC article.
Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Huober J, Fasching PA, Hanusch C, Rezai M, Eidtmann H, Kittel K, Hilfrich J, Schwedler K, Blohmer JU, Tesch H, Gerber B, Höß C, Kümmel S, Mau C, Jackisch C, Khandan F, Costa SD, Krabisch P, Loibl S, Nekljudova V, Untch M, Minckwitz Gv. Huober J, et al. Among authors: fasching pa. Eur J Cancer. 2013 Jul;49(10):2284-93. doi: 10.1016/j.ejca.2013.02.027. Epub 2013 Mar 27. Eur J Cancer. 2013. PMID: 23541564 Clinical Trial.
809 results